Nucleoside prodrugs and uses thereof

1. A compound of general formula I or II

wherein V is phenyl or pyridinyl said phenyl or pyridinyl optionally substituted with one to three substituents selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, or cyano;

B is

R 1 and R 2 are independently selected from H and or COR 4 ;

Y is O or NH;

R 3 is C 1 -C 6 alkyl or COR 4 and,

R 4 is C 1-6 alkyl, C 1-3 alkoxy-C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-3 alkyl, C 1-6 alkoxy or heteroaryl wherein the heteroaryl is a five-membered ring containing one or two heteroatoms selected from nitrogen, oxygen or sulfur or pyridine or a six-membered ring with one or two nitrogen atoms; or,

a pharmaceutically acceptable salt thereof.

2. A compound according to formula I of claim 1 wherein B is B-1.

3. A compound according to claim 2 wherein V is optionally substituted phenyl, R 1 and R 2 are independently hydrogen or COR 4 ; and R 4 is C 1-6 alkyl.

4. A compound according to formula II of claim 1 .

5. A compound according to formula II of claim 3 wherein V is optionally substituted phenyl and B is B-1.

6. A compound according to claim 1 wherein B is B-2.

7. A compound according to claim 6 wherein V is optionally substituted phenyl.

8. A compound according to claim 1 wherein B is B-3.

9. A compound according to claim 8 wherein V is optionally substituted phenyl.

10. A compound according to claim 1 selected from the group consisting of:

4′-azido-cis-5′-O-[4-(R,S)-(3-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3-bromophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3-bromo-4-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3-chloro-4-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-phenyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(4-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(4-bromophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2-bromophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3-bromo-5-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-( 2 ,4-dichlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2-chloro-6-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2,5-dichlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2,4-difluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3-bromo-6-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2-chloro-4-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2,3-difluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-{4-(R,S)-[3,5-di-(trifluoromethyl)phenyl]-2-oxo-1,3,2-dioxaphosphorinan-2-yl}uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3-trifluoromethylphenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2-trifluoromethylphenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3-cyanophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(4-trifluoromethylphenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(3,5-dichlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(S)-(3,5-difluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(S)-(pyrid-4-yl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine, hydrochloride salt;

4′-azido-cis-5′-O-[4-(R,S)-(3,4-dichlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(pyrid-3-yl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine, hydrochloride salt 4′-azido-cis-5′-O-[4-(R,S)-(3-bromopyrid-5-yl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine, hydrochloride salt 4′-azido-cis-5′-O-[4-(R,S)-(2-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2,6-difluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2,6-dichlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(R,S)-(2-fluoro-4-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine 4′-azido-cis-5′-O-[4-(R,S)-(2-fluoro-4-bromophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

2′3′-O-(3-methylbutanoyl)-4′-azido-cis-5′-O-[4-(R,S)-(3-cyanophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-propionate;

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis -pivaloyl-uridine;

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1 ,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis -pentanoyl-uridine;

2′,3′-O-(3-methylbutanoyl)-4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

2′,3′-O-bis-isobutanoyl-4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

2′,3′-O-bis-n-butanoyl-4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1 ,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis -(cyclopropylcarbonyl)uridine;

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1 ,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis -(2-cyclopropylacetyl)-uridine;

2′,3′-O-bis-(oxazole-4-carbonyl)-4′-azido-cis-5′-o-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine;

2′,3′-O-bis-(furan-3-carbonyl)-4′-azido-cis-5′-o-[4-(S)-(3-chlorophenyl) -2-oxo- 1 , 3 , 2 -dioxaphosphorinan-2-yl]uridine;

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis -(2-ethoxyacetyl)-uridine;

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3 ,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis -(2-methoxy-acetyl)-uridine;

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-(ethoxycarbonate);

4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-(isopropoxycarbonate);

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis-(pyrrole-2-carboxyl)uridine;

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis-(pyrazol-5-carboxyl)-uridine;

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis -(pyridine-3-carboxyl)-uridine;

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis-(2-ethoxyacetyl)-uridine;

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2′,3′-O-bis-(2-methoxy-acetyl)-uridine;

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-(ethoxycarbonate);

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-(isopropoxycarbonate); and,

and stereoisomers thereof.

11. A compound according to claim 1 which compound is:

4′-Azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3 ,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-propionate, 4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3 ,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-valeroate, 4′-azido-cis-5′-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3 ,2-dioxaphosphorinan-2-yl]uridine 2′,3′-O-bis-isovaleroate.

12. A method for treating a disease caused by the Hepatitis C Virus (HCV) virus comprising administering to a patient in need thereof, a therapeutically effective quantity of a compound according to claim 1 .

13. The method of claim 12 further co-comprising administering at least one immune system modulator and/or at least one antiviral agent that inhibits replication of HCV.

14. The method of claim 13 wherein the immune system modulator is an interferon, interleukin, tumor necrosis factor or colony stimulating factor.

15. The method of claim 14 wherein the immune system modulator is an interferon or chemically derivatized interferon.

16. The method of claim 13 wherein the antiviral compound is selected from the group consisting of a HCV protease inhibitor, another HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV primase inhibitor and a HCV fusion inhibitor.

17. A method of inhibiting replication in HCV comprising administering a therapeutically effective quantity of a compound according to claim 1 .

18. A pharmaceutical composition comprising a therapeutically effective quantity of a compound according to claim 1 admixed with at least one pharmaceutically acceptable carrier, diluent or excipient.